<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146248</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 10103</org_study_id>
    <nct_id>NCT02146248</nct_id>
  </id_info>
  <brief_title>HSG and Tubal Patency Study</brief_title>
  <official_title>Tubal Patency During the Menstrual Cycle and During Treatment With Hormonal Contraceptives: a Pilot Study in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Jensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' research group is working to develop a highly effective, low cost
      non-surgical method of permanent contraception for women. To support this goal, we need to
      know more about the normal fallopian tube (tube that passes the egg from the ovary into the
      womb). The purpose of this study is to learn about how menstrual cycles and hormonal
      contraceptives affect tubal patency. Normally there is an opening between the tube and uterus
      to permit the flow of fluid and cells. If this opening is blocked, this can result in
      infertility. Tubal patency is when a woman's fallopian tubes are not blocked. Tubal patency
      is determined by an x-ray test called a hystero-(uterus)salpingo-(fallopian tube)graphy
      (HSG). HSG is a standard radiological imaging study that is used to determine if the
      fallopian tubes are open and free of disease. It is commonly done in women with an
      infertility diagnosis. The investigators usually do this test in the first 10 days of the
      menstrual cycle. Sometimes the tubes will appear to be blocked on the HSG when they are
      actually open. The timing of the HSG study during the menstrual cycle, or the use of hormonal
      contraception may make a difference in whether the tubes appear blocked on the HSG when they
      are actually patent.

      The results of the HSG test provide a good model for how our nonsurgical permanent
      contraception method might work. The investigators think that if the tubes are not patent,
      that our treatment will not work as well. Therefore, in this study we want to learn if
      menstrual cycle timing or current hormonal contraception use will affect the patency of the
      tubes as assessed by the HSG. The investigators want to examine the same women to see if
      tubal patency is changes during the menstrual cycle and during the use of a birth control
      pill and the birth control shot.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Bilateral Tubal Patency as Assessed by HSG-follicular</measure>
    <time_frame>follicular phase HSG</time_frame>
    <description>Assessment of patency at follicular phase exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - Luteal</measure>
    <time_frame>luteal phase HSG</time_frame>
    <description>Assessment of patency at luteal phase exam</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - OC HSG</measure>
    <time_frame>HSG on OC</time_frame>
    <description>HSG during OC treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - DMPA HSG</measure>
    <time_frame>HSG on DMPA</time_frame>
    <description>HSG during DMPA treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Bilateral Tubal Patency as Assessed by HSG -- Post DMPA Add Back COC HSG</measure>
    <time_frame>HSG on OC after DMPA</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Tubal Patency</condition>
  <arm_group>
    <arm_group_label>HSG Studies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).
2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined oral contraceptive</intervention_name>
    <description>combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption</description>
    <arm_group_label>HSG Studies</arm_group_label>
    <other_name>pill, birth control pill, COC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DepoProvera</intervention_name>
    <description>injectable hormonal contraceptive</description>
    <arm_group_label>HSG Studies</arm_group_label>
    <other_name>Depo-medroxyprogesterone acetate, DMPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Women between 18 and 40 years old ii. In good health, with regular menstrual cycles that
        occur 24 - 37 days iii. No current use of hormonal contraception or an intrauterine device
        and having had at least one complete menstrual cycle since having stopped hormonal
        contraception before starting the treatment.

        iv. Have a negative urine pregnancy test at the admission visit. v. Have a negative
        chlamydia test at the admission visit. vi. Not be at risk for pregnancy. They will be
        consistently using a non-hormonal contraception method, have a surgically sterile male
        partner with a vasectomy, be abstinent, or be in a same-sex relationship from the screening
        visit through the first study cycle. After starting the combined OC (see Visit 4 below),
        use of a non-hormonal method is no longer required.

        vii. In the opinion of the investigator, willing and able to follow all study requirements,
        including use of the approved study medications (doxycycline, oral contraceptive and DMPA).

        viii. Understand and sign an IRB approved inform consent form prior to screening
        activities.

        ix. Will have diastolic blood pressure (BP) ≤85 mm Hg and systolic BP ≤145 mm Hg after 5
        minutes in sitting position.

        x. Agree not to participate in any other clinical trials during the course of this study.

        Exclusion Criteria:

          -  i. Women with menstrual cycle length of less than 24 or more than 37 days; or with
             spontaneous irregular menstrual cycle length with intra-individual variations of more
             than 5 days ii. Currently pregnant as confirmed by positive high-sensitivity urine
             pregnancy test iii. Women planning pregnancy within their months of study
             participation iv. Currently breast-feeding or within 30 days of discontinuing breast
             feeding v. Current use of a hormonal IUD, or other hormonal contraception (including
             oral contraceptives, contraceptive vaginal rings, contraceptive patches, or
             contraceptive implants) within 30 days prior to screening. NOTE: Discontinuation of
             hormonal contraception or removal of implanted hormonal contraceptives must have been
             for personal reasons unrelated to the purpose of enrollment in this study.

        vi. Undiagnosed abnormal genital bleeding vii. Known hypersensitivity to radio-opaque
        contrast, doxycycline, levonorgestrel, ethinyl estradiol or depo-medroxyprogesterone
        acetate. The active ingredients in the approved medications used in the study.

        viii. Anomalies in the clinical exam or history done at screening visit recognized as
        clinically significant by the investigator.

        ix. Unable to pass a uterine sound at the screening examination. x. A positive test for
        chlamydia at screening, or a history of a positive test within the last 6 months.

        xi. A clinically significant Pap test abnormality, as managed by current local or national
        guidelines that would require treatment over the next 6 months.

        xii. Invasive cancer (past history of any carcinoma or sarcoma, except non-melanoma skin
        cancer) xiii. Body mass index (BMI) &gt;35. xiv. Current use of a non-hormone containing
        (copper) intrauterine device (IUD). NOTE: Removal of an IUD must have been for personal
        reasons unrelated to the purpose of enrollment in this study.

        xv. Smoking if &gt; age 35. xvi. Personal history of venous or arterial thrombosis or
        embolism, or family history in a first-degree relative &lt;55 years of age suggesting familial
        defect in blood coagulation system, which in the opinion of the principal investigator,
        suggests use of a hormonal contraceptive could pose a significant risk.

        xvii. Cerebrovascular or cardiovascular disease. xviii. History of retinal vascular
        lesions, unexplained partial or complete loss of vision.

        xix. Headaches with focal neurological symptoms. xx. History of cholestatic jaundice of
        pregnancy or jaundice with prior steroid use.

        xxi. Use of liver enzyme inducers on a regular basis. xxii. History of involuntary
        infertility, pelvic inflammatory disease (not followed by a normal pregnancy), or known
        gynecologic conditions or surgery that could affect tubal patency (e.g. tubal adhesions,
        endometriosis, hydrosalpinx, salpingectomy, hysterectomy, oophorectomy).

        xxiii. History of a prior HSG showing tubal occlusion on one or both sides.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Jensen, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <results_first_submitted>October 28, 2016</results_first_submitted>
  <results_first_submitted_qc>December 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2017</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jeffrey Jensen</investigator_full_name>
    <investigator_title>Dr. Jeffrey Jensen</investigator_title>
  </responsible_party>
  <keyword>hysterosalpingography, DMPA, combined oral contraceptive, tubal patency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>14 subjects were screened, and 11 signed consent and enrolled. One dropped out prior to the first HSG, and10 completed the 2 natural cycle HSG, 9 completed the COC HSG, 7 the DMPA HSG, and one a final post DMPA HSG after restarting COCs</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HSG Studies</title>
          <description>Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).
2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill.
Combined oral contraceptive: combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
DepoProvera: injectable hormonal contraceptive</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Uterine Sounding</title>
              <participants_list>
                <participants group_id="P1" count="11">one subject dropped out after uterine sound before HSG #1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>HSG 1</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HSG 2</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HSG 3</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HSG 4</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HSG 5</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HSG Studies</title>
          <description>Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).
2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill.
Combined oral contraceptive: combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
DepoProvera: injectable hormonal contraceptive</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nulligravid</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>One or more births</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG-follicular</title>
        <description>Assessment of patency at follicular phase exam</description>
        <time_frame>follicular phase HSG</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Follicular Phase HSG</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG-follicular</title>
          <description>Assessment of patency at follicular phase exam</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>bilateral patent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>blocked</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>McNemar paired. Hypothesis is no change in tubal patency status. All subjects know to have bilateral patency in one of the exams during natural cycle</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4795</p_value>
            <p_value_desc>The two-tailed P value equals 0.4795</p_value_desc>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - Luteal</title>
        <description>Assessment of patency at luteal phase exam</description>
        <time_frame>luteal phase HSG</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tubal Patency Change</title>
            <description>Change in tubal patency after OC treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - Luteal</title>
          <description>Assessment of patency at luteal phase exam</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>bilateral tubal patency</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>blocked</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - OC HSG</title>
        <description>HSG during OC treatment</description>
        <time_frame>HSG on OC</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HSG 3</title>
            <description>OC HSG</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - OC HSG</title>
          <description>HSG during OC treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>bilateral tubal patency</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>blocked</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - DMPA HSG</title>
        <description>HSG during DMPA treatment</description>
        <time_frame>HSG on DMPA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HSG 4</title>
            <description>DMPA HSG</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG - DMPA HSG</title>
          <description>HSG during DMPA treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>bilateral patubal patency</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>blocked</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG -- Post DMPA Add Back COC HSG</title>
        <time_frame>HSG on OC after DMPA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HSG 5</title>
            <description>post DMPA OC HSG</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bilateral Tubal Patency as Assessed by HSG -- Post DMPA Add Back COC HSG</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>bilateral patent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>blocked</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>May 2014 - Feb 2015</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HSG Studies</title>
          <description>Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).
2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill.
Combined oral contraceptive: combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
DepoProvera: injectable hormonal contraceptive</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a descriptive pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey T. Jensen</name_or_title>
      <organization>OHSU</organization>
      <phone>503-629-4058</phone>
      <email>jensenje@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

